Download PDF
Thromb Haemost 1988; 59(02): 164-170
DOI: 10.1055/s-0038-1642747
Original Articles
Schattauer GmbH Stuttgart

Effect of SC 38249, a Novel Substituted Imidazole, on Platelet Aggregation In Vitro and In Vivo

N Lad
Searle Research & Development, High Wycombe, Buckinghamshire, UK
,
A C Honey
Searle Research & Development, High Wycombe, Buckinghamshire, UK
,
D O Lunt
Searle Research & Development, High Wycombe, Buckinghamshire, UK
,
R F G Booth
Searle Research & Development, High Wycombe, Buckinghamshire, UK
,
J Westwick
1   Department of Pharmacology, Royal College of Surgeons of England, Lincoln's Inn Fields, London WC2A 3PN, UK
,
P W Manley
Searle Research & Development, High Wycombe, Buckinghamshire, UK
,
D P Tuffin
Searle Research & Development, High Wycombe, Buckinghamshire, UK
› Author Affiliations
Further Information

Publication History

Received 16 June 1987

Accepted after revision 03 November 1987

Publication Date:
21 May 2018 (online)

  PDF Download  Permissions and Reprints

Summary

SC 38249 ((RS)-l-(2,3-bis-[(4-methoxyphenyl)methoxy] propyl)-lH-imidazole) caused dose-related inhibition of collagen- induced thromboxane A2 formation in human platelet rich plasma (IC50: 9.9 ± 1.0 μM) accompanied by a dose-dependent increase in plasma PGE2. Broad inhibitory activity was evident against human platelet aggregatory and secretory responses in vitro.IC50 values of 11.9 ± 1.9 μM (0.64 mM arachidonic acid), 18.3 ± 3.8 μM (0.5 μg ml−-1collagen) and 37.6 ± 6.1 μM (25 nM Paf-acether) were obtained against maximum increase in PRP light transmission achieved by each agonist. Although less potent, SC 38249 retained significant inhibitory activity against PRP responses induced by a higher (3.0 μg ml−-1) concentration of collagen (IC50: 272.5 ± 24.6 μM), and against Paf-acether-induced responses in PRP pre-treated with 10 μM indomethacin (I.C.50: 192.0 ± 16.1 μM).Experimental animal studies confirmed the in vitroanti-aggregatory efficacy of SC 38249, since significant inhibitory activity was observed against Paf-acether and ADP-induced responses in dog PRP ex vivo,anti-Forssman antibody-induced thrombocytopoenia in anaesthetized guinea pigs, and collagen-induced intravascular aggregation in anaesthetized rabbits. Thus, SC 38249 is a novel thromboxane synthase inhibitor which possesses interesting anti-aggregatory properties which cannot wholly be attributed to prevention of platelet thromboxane A2 formation.

Keywords

SC 38249 - Thromboxane synthase inhibitor - Anti-aggregatory properties
 

  • References

  • 1 Hamberg M, Svensson J, Samuellson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U.S. A. 1975; 72: 2994-2998
    CrossrefPubMedGoogle Scholar
  • 2 Bhagwat SS, Hamann PR, Still WC. Synthesis of thromboxane A2 . J Am Chem Soc 1985; 107: 6372-6376
    CrossrefPubMedGoogle Scholar
  • 3 Miyamoto T, Taniguchi K, Tanouchi T, Hirata F. Selective inhibitor of thromboxane synthetase: pyridine and its derivatives. Adv Prost Thrombox Res 1980; 6: 443
    PubMedGoogle Scholar
  • 4 Randall MJ, Parry MJ, Hawkeswood E, Cross PE, Dickinson RP. UK 37248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. Thromb Res 1981; 23: 145-162
    CrossrefPubMedGoogle Scholar
  • 5 Ambler J, Butler KD, Ku EC, Maguire ED, Smith JR, Wallis RB. CGS 12970 A novel long-acting thromboxane synthetase inhibitor. Br J Pharmac 1985; 86: 497-504
    CrossrefPubMedGoogle Scholar
  • 6 Kato K, Ohkawa S, Terao S, Terashita Z, Nishikawa K. Thromboxane synthetase inhibitors (TXSI). Design, synthesis and evaluation of a novel series of opyridyl alkenoic acids. J Med Chem 1985; 28: 287-294
    CrossrefPubMedGoogle Scholar
  • 7 Olson RW, Cohen DS, Ku EC, Kimble EF, Renfroe HB, Smith EF. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben. Eur J Pharmacol 1987; 133: 265-273
    CrossrefPubMedGoogle Scholar
  • 8 Hall ER, Chen Y-C, Ho T, Wu KK. The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits. Thromb Res 1982; 27: 501-511
    CrossrefPubMedGoogle Scholar
  • 9 Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR. Effect of OKY 1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog. Eur J Pharmac 1984; 105: 285-291
    CrossrefPubMedGoogle Scholar
  • 10 Tomoda H. Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). Am Heart J 1986; 112: 696-704
    CrossrefPubMedGoogle Scholar
  • 11 Katayama Y, Shimizu J, Memezawa H, Minamisawa H, Suzuki S, Sugimoto S, Terashi A. Protective effect of thromboxane A2synthetase inhibitor (trapidil) on acutely-induced cerebral ischaemia. Brain Nerve 1986; 38: 925-931
    PubMedGoogle Scholar
  • 12 Butler KD, Butler PA, Shand RA, Ambler J, Wallis RB. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970(3-methyl-2-(3-pyridyl)-l-indoleoctanoic acid) and dazoxiben. Thromb Res 1987; 45: 751-761
    CrossrefPubMedGoogle Scholar
  • 13 Manley PW, Allanson NM, Booth RF G, Buckle PE, Kuzniar EJ, Lad N, Lai SM F, Lunt DO, Tuffin DP. Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitors. J Med Chem 1987; 30: 1588-1595
    CrossrefPubMedGoogle Scholar
  • 14 Lad N, Lunt DO, Tuffin DP. The effect of thromboxane A2 synthesis inhibitors on platelet aggregation in whole blood. Thromb Res 1987; 46: 555-566
    CrossrefPubMedGoogle Scholar
  • 15 Mehta P, Mehta J, Ostrowski N, Aguila E. Potentiation of platelet aggregation by chronolume. Thromb Res 1983; 32: 509-512
    CrossrefPubMedGoogle Scholar
  • 16 Thompson NT, Scrutton MC. Inhibition by luciferin-luciferase reagents of aggregatory responses to excitatory agonists in washed platelet suspensions. Thromb Res 1985; 38: 109-119
    CrossrefPubMedGoogle Scholar
  • 17 Banerjee AK, Tuffin DP, Walker JL. Pharmacological effects of (±)-ll-deoxy, 16-phenoxy prostaglandin Ej derivatives in the cardiovascular system. Br J Pharmac 1985; 84: 71-80
    PubMedGoogle Scholar
  • 18 Honey AC, Lad N, Tuffin DP. Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. Thromb Haemostas 1986; 56: 80-85
    PubMedGoogle Scholar
  • 19 Smith GM, Freuler F. The measurement of intravascular aggregation by continuous platelet counting. Bibl Anat 1973; 12: 257-265
    PubMedGoogle Scholar
  • 20 Steinhauer HB, Lubrich I, Gunter B, Schollmeyer P. Response of human platelets to inhibition of thromboxane synthesis. Clin Haemorheol 1983; 3: 1-12
    PubMedGoogle Scholar
  • 21 Ku EC, McPherson SE, Signor C, Chertock H, Cash WD. Characterization of imidazo[l,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivobiochemical models. Biochem Biophys Res Comm 1983; 112: 899-906
    CrossrefPubMedGoogle Scholar
  • 22 Gorman RR, Johnson RA, Spilman CH, Aiken JW. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3’-pyridinyl- methyl)benzofuran-2-carboxylate. Prostaglandins 1983; 26: 325-342
    CrossrefPubMedGoogle Scholar
  • 23 Hiraku S, Wakitani K, Katsube N, Kawasaki A, Tsuboshima M, Naito J, Ujiie A, Komatsu H, Iizuka K. Pharmacological studies on OKY 1581 a selective thromboxane synthetase inhibitor. Adv Prost Throm- box Res 1983; 11: 241-244
    PubMedGoogle Scholar
  • 24 Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res 1980; 20: 219-230
    CrossrefPubMedGoogle Scholar
  • 25 Bertele V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, De Gaetano G. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclo-oxygenase products. Blood 1984; 63: 1460-1466
    PubMedGoogle Scholar
  • 26 Dale J, Thaulow E, Myhre E, Parry J. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Thromb Haemostas. 1983 50.
    PubMedGoogle Scholar
  • 27 Ito T, Ogawa K, Sakai K, Watanabe J, Satake T, Kayama N, Hiraku S, Naito J. Effects of a selective inhibitor of thromboxane synthetase (OKY 1581) in humans. Adv Prost Thrombox Res 1983; 11: 245-251
    PubMedGoogle Scholar
  • 28 Hornby EJ, Skidmore IF. Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production. Biochem Pharmacol 1982; 31: 1158-1160
    CrossrefPubMedGoogle Scholar
  • 29 Rajtar G, Cerletti C, Castagnoli MN, Bertele V, De Gaetano G. Prostaglandins and human platelet aggregation: implications for the anti-aggregating activity of thromboxane synthetase inhibitors. Biochem Pharmacol 1985; 34: 307-310
    CrossrefPubMedGoogle Scholar
  • 30 Grimm LJ, Knapp DR, Senator D, Halushka PV. Inhibition of platelet thromboxane synthesis by 7-(l-imidazoyl)heptanoic acid, dissociation from inhibition of aggregation. Thromb Res 1981; 24: 307-317
    CrossrefPubMedGoogle Scholar
  • 31 Gorman RR. Biology and biochemistry of thromboxane synthetase inhibitors. Adv Prost Thrombox Res 1983; 11: 235-240
    PubMedGoogle Scholar
  • 32 Marcus AJ, Safier LB, Ullman HL, Wong KT H, Brockman MJ, Weksler BB, Kaplan KL. Effects of acetyl glyceryl ether phosphoryl- choline on human platelet function in vitro. . Blood 1981; 58: 1027-1031
    PubMedGoogle Scholar
  • 33 McManus LM, Hanahan DJ, Pinckard RN. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest 1981; 67: 903-906
    CrossrefPubMedGoogle Scholar
  • 34 Chignard M, Coeffier E, Benveniste J. Role of Paf-acether and related ether-lipid metabolism in platelets. Adv Exp Med Biol 1985; 192: 309-326
    PubMedGoogle Scholar
  • 35 Tuffin DP, Davey P, Dyer RL, Lunt DO, Wade PJ. Specific binding of [3H]-1 -O-octadecyl-Paf-acether to washed human platelets. Adv Exp Med Biol 1985; 192: 83-96
    PubMedGoogle Scholar
  • 36 Darlow G. The effect of Forssman antibody on the circulation and respiration of the guinea pig. J Physiol 1965; 181: 350-364
    CrossrefPubMedGoogle Scholar
  • 37 Darlow G, Gough GF, Tanalp R. The involvement of the complement system in the pressor response to the injection of Forssman antibody in the guinea pig. J Physiol 1970; 206: 481-493
    CrossrefPubMedGoogle Scholar
  • 38 Newman S, Glovsky MM, Ghekiere MS, Alenty A. Quantitative requirements for C3 to induce Forssman systemic shock and cutaneous haemorrhagic vasculitis in guinea pigs. J All Clin Immunol 1977; 59: 327-333
    CrossrefPubMedGoogle Scholar
  • 39 Nagai H, Kurimoto Y, Koda A. Immunopharmacological approach to Forssman shock. Microbiol Immunol 1980; 24: 649-655
    CrossrefPubMedGoogle Scholar
  • 40 Pelczarska AB, Roszkowski AP. Inhibitors of Forssman guinea pig anaphylaxis. J Pharmacol Exp Ther 1973; 185: 116-126
    PubMedGoogle Scholar